WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience Synaptic Systems Antibody Company
 QUICK SEARCH:   [advanced]


     
-


HOME
  |  
SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, May 2, 2007, 27(18):4957-4968; doi:10.1523/JNEUROSCI.5417-06.2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Choi, H. B.
Right arrow Articles by McLarnon, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choi, H. B.
Right arrow Articles by McLarnon, J. G.

 Previous Article  |  Next Article 

Neurobiology of Disease
Modulation of the Purinergic P2X7 Receptor Attenuates Lipopolysaccharide-Mediated Microglial Activation and Neuronal Damage in Inflamed Brain

Hyun B. Choi,1,2 * Jae K. Ryu,1 * Seung U. Kim,2,3 and James G. McLarnon1

1Department of Anesthesiology, Pharmacology, and Therapeutics and 2Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z3, and 3Brain Disease Research Center, Ajou University, Suwon, Korea 443-749

Correspondence should be addressed to Dr. James G. McLarnon, Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, British Columbia, Canada V6T 1Z3. Email: mclarnon{at}interchange.ubc.ca

We investigated the involvement and roles of the ionotropic purinergic receptor P2X7R in microglia in mediating lipopolysaccharide (LPS)-induced inflammatory responses and neuronal damage in rat striatum. A detailed in vivo study showed that LPS injection into striatum markedly increased the expression of P2X7R in microglia compared with control (saline)-injected animals. Additionally, LPS injection upregulated a broad spectrum of proinflammatory mediators, including inducible nitric oxide synthase (nitric oxide production marker), 3-nitrotyrosine (peroxynitrite-mediated nitration marker), 4-hydroxynonenal (lipid peroxidation marker), and 8-hydroxy-2'-deoxyguanosine (oxidative DNA damage marker), and reduced neuronal viability. The P2X7R antagonist oxidized ATP (oxATP) was effective in attenuating expressions of all inflammatory mediators and in addition inhibited LPS-induced activation of the cellular signaling factors p38 mitogen-activated protein kinase and transcriptional factor nuclear factor {kappa}B. Most importantly, in vivo, oxATP blockade of P2X7R also reduced numbers of caspase-3-positive neurons and increased neuronal survival in LPS-injected brain. In vitro, LPS stimulation of cultured human microglia enhanced cellular expressions of a host of proinflammatory factors, including cyclooxygenase-2, interleukin-1ß (IL-1ß), IL-6, IL-12, and tumor necrosis factor-{alpha}; all factors were inhibited by oxATP. A novel finding was that LPS potentiated intracellular [Ca2+]i mobilization induced by the P2X7R ligand 2',3'-O-(4-benzoyl-benzoyl) ATP, which could serve as a mechanistic link for P2X7R amplification of inflammatory responses. Our results suggest critical roles for P2X7R in mediating inflammation and inhibition of this subtype purinergic receptor as a novel therapeutic approach to reduce microglial activation and confer neuroprotection in inflamed and diseased brain.

Key words: P2X7 receptor; lipopolysaccharide; microglia; inflammation; cytokines; oxidized ATP


Received Dec. 14, 2006; revised March 13, 2007; accepted March 28, 2007.

Correspondence should be addressed to Dr. James G. McLarnon, Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, British Columbia, Canada V6T 1Z3. Email: mclarnon{at}interchange.ubc.ca




This article has been cited by other articles:


Home page
J. Neurosci.Home page
E. Avignone, L. Ulmann, F. Levavasseur, F. Rassendren, and E. Audinat
Status Epilepticus Induces a Particular Microglial Activation State Characterized by Enhanced Purinergic Signaling
J. Neurosci., September 10, 2008; 28(37): 9133 - 9144.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
A. V. Gourine, N. Dale, E. Llaudet, D. M. Poputnikov, K. M. Spyer, and V. N. Gourine
Release of ATP in the central nervous system during systemic inflammation: real-time measurement in the hypothalamus of conscious rabbits
J. Physiol., November 15, 2007; 585(1): 305 - 316.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
C. Matute, I. Torre, F. Perez-Cerda, A. Perez-Samartin, E. Alberdi, E. Etxebarria, A. M. Arranz, R. Ravid, A. Rodriguez-Antiguedad, M. Sanchez-Gomez, et al.
P2X7 Receptor Blockade Prevents ATP Excitotoxicity in Oligodendrocytes and Ameliorates Experimental Autoimmune Encephalomyelitis
J. Neurosci., August 29, 2007; 27(35): 9525 - 9533.
[Abstract] [Full Text] [PDF]



-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help

-
Copyright 2008 by Society for Neuroscience ONLINE ISSN: 1529-2401
-